Precision in practice for Advanced/Recurrent Endometrial Cancer
| Target Professions: | DO, MD, Pharmacist, Nurse |
| Target Specialties: | Gynecologic Oncology, Oncology |
| Credits Available: | 4.75 hours of AMA PRA Category 1 Credit™, ANCC, and ACPE. MOC Points Available |
Endometrial cancer is among the few cancers increasing in incidence and mortality in the United States. In its early stages, endometrial carcinoma has a five-year relative survival rate of 96%, but it decreases to 18% for those with metastases. Surprisingly, mortality has been increasing faster than incidence. This is attributed to increasing rates of advanced cancers, higher-risk histologies, and older age of first diagnosis. Yet, there have also been increases in diagnoses in women aged less than 50 years, based on Surveillance, Epidemiology, and End Results (SEER) program data.
While the incidence and mortality has been increasing across all racial groups, the rate of increase for Black women has been the steepest. Adjusting for the higher rate of hysterectomy in Black women compared with White women, the differing rates of this cancer in these groups exemplify this racial disparity.
These statistics demonstrate the need for new therapeutics and subsequent education on their use in this field. To improve clinical outcomes, clinicians treating patients for advanced/recurrent endometrial cancer need to understand biomarker testing and molecular classification of disease, newest guidelines on management, and the evidence underlying these recommendations. Along with this, clinicians must be aware of the most effective ways to manage possible adverse events. To these ends, this educational initiative will allow clinicians managing patients with advanced/recurrent endometrial cancer to learn and discuss the crucial points in diagnosing and managing these patients to best increase long-term survival.
CME/CE Accreditation Information
Itinerary
Part 1
The following questions are intended to assess your knowledge and practice of key aspects in the management of patients with advanced/recurrent endometrial cancer.
This module will discuss the emerging use of molecular classification in endometrial cancer.
This module will cover key clinical trials in endometrial cancer. The emphasis will be on advanced, metastatic, recurrent endometrial cancer.
In this module, we will present two endometrial cancer cases to cover the interpretation of molecular classification as it applies to endometrial cancer treatment.
In this module, we will cover the recognition and management of immune-related adverse events (irAEs) associated with endometrial cancer treatment.
The following questions are intended to assess your gained knowledge and practice of key aspects in the management of patients with advanced/recurrent endometrial cancer.
During this session, we will review the self-study modules and discuss approaches to treatment that offer optimal care to patients with endometrial cancer.
Part 2
Tonya, is a 65-year-old woman, presenting to her primary care physician with a 3-month history of persistent abdominal bloating, early satiety, and intermittent pelvic pain, with vaginal spotting.
In light of the information reviewed and discussed during this program, please share an action plan that you will implement to improve the diagnosis and management for your patients with advanced/recurrent endometrial cancer.
During this session, we will review the patient case and discuss treatment plans. Additionally, we will share our action plans and how this CME activity will shape our practice regarding patient care.
Interested in becoming a Group Leader?
Ideal group leaders should be involved in the care of patients with advanced/recurrent endometrial cancer. Apply Now
